HOME >> BIOLOGY >> NEWS
Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

SAN DIEGO, Calif., November 16, 2005 -- Results from a Phase 2 rheumatoid arthritis (RA) study assessing the safety and efficacy of golimumab (CNTO 148), a fully-human anti-TNF-alpha therapy, showed that it achieved the primary endpoint of the study. In this dose-ranging trial, more than 60 percent of patients with moderately to severely active RA treated with golimumab and methotrexate (MTX) experienced at least 20 percent improvement in arthritis symptoms at week 16. Additionally, one-quarter of patients receiving golimumab and MTX achieved remission as evaluated by Disease Activity Score 28 (DAS28). These findings will be presented this week at the American College of Rheumatology 2005 Annual Scientific Meeting.

"When treating a debilitating disease like RA, it is important to have several treatment options, and we are encouraged by the safety and efficacy data we have seen thus far for golimumab," said Jonathan Kay, MD, Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital, Associate Clinical Professor of Medicine, Harvard University School of Medicine and lead study investigator.

Golimumab, developed by Centocor, Inc. and Schering-Plough, is a fully-human anti-TNF-alpha IgG1 monoclonal antibody that targets and neutralizes both the soluble and the membrane-bound form of TNF-alpha. Golimumab is currently being investigated for administration by either subcutaneous (SC) injection or intravenous (IV) infusion.

Data from the study showed that significantly more patients in all groups receiving SC injections of golimumab plus MTX achieved ACR 50 response (marked improvement in arthritis symptoms according to the American College of Rheumatology scoring criteria) versus patients receiving placebo plus MTX. Adults with active RA for at least three months' duration despite MTX therapy were randomized to one of five treatment groups: placebo every two weeks or golimumab 50 or 100 mg every two weeks or every four wee
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. ASBMB Schering-Plough Award lecture to focus on histone modifications in transcription
2. Cardiac patches stimulate regeneration, improve function after heart attack
3. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
4. Critical protein prevents DNA damage from persisting through generations
5. Early environmental exposure may accelerate age-related neurodegeneration
6. First demonstration of new hair follicle generation in an animal model
7. Enhanced environment restores memory in mice with neurodegeneration
8. Liver regeneration may be simpler than previously thought
9. Invasive grass may impede forest regeneration
10. Research project tackles regeneration gap
11. Whole body regeneration from a blood vessel

Post Your Comments:
(Date:7/29/2014)... UK overseas territory of Ascension Island, one of the ... a renaissance. , Writing in the journal Biodiversity ... and Ascension Island Government Conservation Department report that the ... Atlantic outpost has increased by more than 500 per ... as 24,000 nests are now estimated to be laid ...
(Date:7/29/2014)... Schools of Dentistry (UM SOD) and Medicine (UM ... a five-year $10.7 million grant award from the ... of the National Institutes of Health to study ... (STDs). The grant, which renews a previous $12 ... direction for the research by studying chlamydial and ...
(Date:7/29/2014)... for parents of preterm babies latest research from the ... they become teenagers, the brains of many preterm children can ... A study conducted by the University,s Robinson Research Institute ... experiences no brain injury in early life, their cognitive abilities ... term-born peers. , However, the results of the study, published ...
Breaking Biology News(10 mins):Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Preterm children's brains can catch up years later 2
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... July 29, 2014  The Society for Clinical ... updated program for the 9 th annual ... in Amelia Island , Florida.  The focus ... remains unchanged, however, the topics and format will ... opportunity among all stakeholders with a continued focus ...
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, Inc. ... advancing a new standard of respiratory critical care, will ... August 5, 2014 before the open of the ... will host a live teleconference and webcast at ... conference call, Discovery Labs, management will discuss the ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
Cached News: